Michael W. Deininger
University of Michigan · 874 works · 52,698 citations · h-index 100
Top works
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
- Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance
- The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- The molecular biology of chronic myeloid leukemia
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- The development of imatinib as a therapeutic agent for chronic myeloid leukemia
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
- The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
- High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib
- Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib